Moneycontrol PRO

Buy Sanofi India; target of Rs 8300: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 8300 in its research report dated July 26, 2022.

July 28, 2022 / 08:42 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Sanofi India

Emphasis on leveraging the digital platform and divestment of the slow-moving business is expected to drive OPM expansion, leading to a high single-digit PAT CAGR over the next two years. High-growth visibility from chronics, strong and debt-free balance sheet, sturdy dividends, and healthy cash position are the key positives. Sanofi has declared a special interim dividend of Rs 193 per share for CY2022.


We retain our Buy recommendation on the stock of Sanofi with a revised PT of Rs 8300 Sanofi has reported a weak result for Q2CY22, though the numbers are not comparable on a y-o-y basis due to divesture of business.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Sanofi India - 270722 - khan

Broker Research
first published: Jul 28, 2022 08:42 pm
ISO 27001 - BSI Assurance Mark